Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIANO: Proteasome inhibitor and IMiDs around autologous stem cell transplantation for untreated multiple myeloma
jRCTs031180335Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of bortezomib, cyclophosphamide, dexamethasone, lenalidomide, melphalan and 1 more in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: CR rate at day 100 from autologous transplantation. Started Apr 2014; status: completed.
02
Drugs
bortezomibcyclophosphamidedexamethasonelenalidomidemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs031180335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180335.